More than 20 million Americans suffer from chronic kidney disease, and every year more than 100,000 people begin dialysis treatment for kidney failure in the U.S. Patients on dialysis suffer significant economic challenges and poor health outcomes, including job loss, malaise, depression, and repeated infections and hospital readmissions.
Significant market failures have contributed to the lack of effective, efficient, patient-centric treatments for kidney failure. Medicare’s ESRD Program entitles every American suffering from kidney failure to lifesaving treatments at a cost of nearly $35 billion annually, which exceeds the total annual budget of the National Institutes of Health. Despite America’s commitment to provide care, there has been little innovation in the field of kidney disease treatment for decades. A prize competition has the power to catalyze the radical degree of change patients deserve and science is poised to make possible.
The Kidney Disease XPRIZE will challenge teams to overcome decades of stagnation in kidney disease treatment. The winning team will develop a wearable or implantable, tether-free, needle-free, and self-regulating renal replacement therapy. The therapy must improve toxin clearance as well as fluid, electrolyte, and endocrine regulation, and address the challenges of vascular access, bleeding, clotting and bio-fouling. The technology developed by this prize will bypass perverse incentives that hinder innovation, and develop new technologies for treating kidney failure, resulting in improved patient and societal outcomes.
To find out how you can help support this XPRIZE, please email [email protected].